April, 05 2026 Sunday 12:33 Hrs
Last update 11-9-2025
  • SENSEX :   73,319.55

  • Commodity broking firm in India185.23( 0.25%) 02-Apr-2026
top-arrow-market
Sensex 73319.55 185.23  (0.25) 02-Apr-2026
Previous Day Close
73134.32
Today's High/Low
High Low
  •  
  •  
73568.54 71545.81

Hot Pursuit - Detailed News

Syngene Intl tumbles after MD & CEO Peter Bains resigns; Siddharth Mittal to take charge
30-Mar-26   10:15 Hrs IST
Following his exit, the board has approved the appointment of Siddharth Mittal as an additional director, designated as MD & CEO with effect from 1 July 2026.

Mittal previously served as MD and CEO of Biocon. He joined the company in May 2013 and served as president & chief financial officer until November 2019. He brings over two decades of experience in strategic finance, M&A, and general management.

During his tenure, he contributed to the growth of the biosimilars business and its transition into Biocon Biologics in 2019. Under Siddharth's leadership, Biocon moved decisively into complex peptides and GLP-1 therapies, stepping into one of the most strategically significant segments in modern pharma. He also led the company's entry into the Generic Formulations segment, building a portfolio of over 20 products across global markets.

Meanwhile, the board has also approved the redesignation of Kiran Mazumdar-Shaw from non-executive chairperson to executive chairperson, subject to shareholders' approval.

Syngene International is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors.

The company's consolidated net profit declined 88.56% to Rs 15 crore on 2.82% fall in revenue from operations to Rs 917.1 crore in Q3 FY26 over Q3 FY25.

Powered by Capital Market - Live News

Top
Attention Investor:
Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers/Depository Participant.     KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, ,Mutual ).    No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.